Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
2 clinical trials · Condition
◉ Watch Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
| Record | Firm | Date |
|---|---|---|
| Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG） (NCT03787992) | Allist Pharmaceuticals, Inc. | 2019-05-30 |
| AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT02296125) | AstraZeneca | 2014-12-03 |
Track Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer automatically
Every clearance here is in the API, with alerts when new ones post.